Ligand Pharmaceuticals Incorporated (LGND) Earnings History
Annual and quarterly earnings data from 1994 to 2024
Loading earnings history...
EPS Growth Rates (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2024 | 93.4% | -13.5% | -2.4% |
| 2023 | 73.3% | 9.1% | 39.7% |
| 2022 | 73.1% | 1.5% | -17.0% |
| 2021 | 74.3% | 43.0% | 23.7% |
| 2020 | 81.4% | 22.9% | -1.8% |
Download Data
Export LGND earnings history in CSV or JSON format
Free sign-in required to download data
Ligand Pharmaceuticals Incorporated (LGND) Earnings Overview
As of March 5, 2026, Ligand Pharmaceuticals Incorporated (LGND) reported trailing twelve-month net income of $49M, reflecting -1.1% year-over-year growth. The company earned $2.41 per diluted share over the past four quarters, with a net profit margin of -0.0%.
Looking at the long-term picture, LGND's historical earnings data spans multiple years. The company achieved its highest annual net income of $629M in fiscal 2019.
Ligand Pharmaceuticals Incorporated maintains positive profitability with a gross margin of 0.9%, operating margin of -0.1%, and net margin of -0.0%. The company continues to generate positive earnings from operations. View revenue history →
Compared to industry peers including RPRX ($765M net income, 0.3% margin), INVA ($271M net income, 0.6% margin), BTX (N/A net income, 0.9% margin), LGND has room to improve margins relative to the peer group. Compare LGND vs RPRX →
Peer Comparison
Earnings metrics vs industry competitors
Historical Data
31 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | -$4M | -107.7% | -$23M | $-0.22 | -2.4% | -13.5% |
| 2023 | $52M | +256.3% | $12M | $2.94 | 39.7% | 9.1% |
| 2022 | -$33M | -158.4% | $3M | $-1.98 | -17.0% | 1.5% |
| 2021 | $57M | +2014.2% | $104M | $3.34 | 23.7% | 43.0% |
| 2020 | -$3M | -100.5% | $38M | $-0.18 | -1.8% | 22.9% |
| 2019 | $629M | +339.1% | $807M | $31.85 | 523.2% | 671.0% |
| 2018 | $143M | +1041.5% | $164M | $5.96 | 57.0% | 65.1% |
| 2017 | $13M | +867.5% | $68M | $0.53 | 8.9% | 48.2% |
| 2016 | -$2M | -100.6% | $44M | $-0.08 | -1.5% | 40.3% |
| 2015 | $257M | +2039.9% | $27M | $12.12 | 357.8% | 38.0% |
See LGND's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs LGND Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare LGND vs AGIO
See how LGND stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is LGND growing earnings?
LGND EPS of $2.41 reflects slowing growth at -1.1%, below the 5-year CAGR of N/A. TTM net income is $49M. Expansion rate has moderated.
What are LGND's profit margins?
Ligand Pharmaceuticals Incorporated net margin is -0.0%, with operating margin at -0.1%. Below-average margins reflect competitive or cost pressures.
How consistent are LGND's earnings?
LGND earnings data spans 1994-2024. The current earnings trend is -1.1% YoY. Historical data enables comparison across business cycles.